However, all homozygous tumors would be classified as malignant in accordance with the newly implemented WHO classification 2021 [165] due to CDKN2A/B homozygous deletion as an independent criterion of WHO grade 3 meningiomas. This evidence concerns the gene CDKN2A and meningioma.